TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
10x Genomics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products and services revenue | $612.70M | $608.76M | $596.69M | $595.91M | $599.45M | $607.28M | $610.46M | – | – | – | – | – | 99.3% | +2.2% |
| Consumables | $530.20M | $521.63M | $507.18M | $498.96M | $497.28M | $498.45M | $493.43M | $500.22M | $488.38M | $477.51M | $479.55M | $470.84M | 85.9% | +6.6% |
| Spatial | $159.54M | $153.64M | $143.98M | $138.81M | $133.11M | $125.96M | $121.12M | $107.50M | $91.92M | $74.36M | $59.24M | $48.43M | 25.9% | +19.9% |
| Instruments | $46.39M | $53.23M | $56.78M | $65.67M | $72.72M | $82.08M | $92.72M | $106.76M | $122.65M | $129.75M | $123.47M | $107.41M | 7.5% | -36.2% |
| Services | $36.11M | $33.91M | $32.73M | $31.28M | $29.45M | $26.75M | $24.32M | $22.56M | $20.59M | $18.19M | $15.70M | $12.74M | 5.9% | +22.6% |
| Spatial | $27.05M | $31.25M | $34.11M | $38.17M | $42.51M | $48.80M | $57.50M | $71.33M | $82.62M | $85.66M | $75.61M | $55.45M | 4.4% | -36.4% |
| License and royalty revenue | $4.21M | $30.02M | $46.14M | $45.91M | $45.02M | $17.38M | $321.00K | – | – | – | – | – | 0.7% | -90.6% |
| Single Cell | – | – | – | $27.50M | $30.21M | $33.28M | $35.21M | $35.43M | $40.02M | $44.09M | $47.87M | $51.96M | – | – |
| Single Cell | – | – | – | $360.15M | $364.17M | $372.49M | $372.31M | $392.72M | $396.46M | $403.15M | $420.32M | $422.41M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $327.17M | $348.30M | $358.77M | $363.82M | $371.77M | $358.71M | $347.77M | $364.39M | $375.57M | $374.03M | $373.19M | $354.97M | 53.0% | -12.0% |
| United States | $315.01M | $336.39M | $346.51M | $351.84M | $359.32M | $345.50M | $334.32M | $349.35M | $360.73M | $359.45M | $360.09M | $343.60M | 51.1% | -12.3% |
| Europe, Middle East and Africa | $171.91M | $166.67M | $161.72M | $158.08M | $154.31M | $156.94M | $159.76M | $160.52M | $154.69M | $148.58M | $142.28M | $134.69M | 27.9% | +11.4% |
| Asia-Pacific | $117.83M | $123.81M | $122.33M | $119.91M | $118.39M | $109.02M | $103.26M | $104.84M | $101.47M | $102.85M | $103.26M | $101.32M | 19.1% | -0.5% |
| China | $61.02M | $69.22M | $70.26M | $69.85M | $69.69M | $60.26M | $57.30M | $54.44M | $51.84M | $50.86M | $50.97M | $55.49M | 9.9% | -12.4% |
| Asia-Pacific (excluding China) | $56.81M | $54.59M | $52.07M | $50.06M | $48.70M | $48.76M | $45.96M | $50.40M | $49.63M | $51.99M | $52.29M | $45.83M | 9.2% | +16.7% |
| Americas (excluding United States) | $12.17M | $11.92M | $12.26M | $11.98M | $12.45M | $13.21M | $13.45M | $15.03M | $14.85M | $14.58M | $13.10M | $11.38M | 2.0% | -2.3% |
From the segment and revenue-disaggregation notes of 10x Genomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.